Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma

The inhaled corticosteroid fluticasone furoate (FF) and the long-acting β(2) agonist vilanterol (VI) are in development as a combined once-daily therapy for asthma and chronic obstructive pulmonary disease. Our study objectives were to compare the efficacy and safety of once-daily FF/VI with FF alon...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Byrne, Paul M., Bleecker, Eugene R., Bateman, Eric D., Busse, William W., Woodcock, Ashley, Forth, Richard, Toler, William T., Jacques, Loretta, Lötvall, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938760/
https://www.ncbi.nlm.nih.gov/pubmed/24136330
http://dx.doi.org/10.1183/09031936.00064513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938760/
https://www.ncbi.nlm.nih.gov/pubmed/24136330
http://dx.doi.org/10.1183/09031936.00064513

Ejemplares similares